Aurobindo Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AUROBINDO PHARMA
AUROBINDO PHARMA has five hundred and sixty-two approved drugs.
There are twenty-five tentative approvals on AUROBINDO PHARMA drugs.
Summary for Aurobindo Pharma
| US Patents: | 0 |
| Tradenames: | 421 |
| Ingredients: | 393 |
| NDAs: | 562 |
| Patent Litigation for Aurobindo Pharma: | See patent lawsuits for Aurobindo Pharma |
| PTAB Cases with Aurobindo Pharma as petitioner: | See PTAB cases with Aurobindo Pharma as petitioner |
Drugs and US Patents for Aurobindo Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aurobindo Pharma | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | dapagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 211489-002 | Apr 6, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aurobindo Pharma Ltd | GLIMEPIRIDE | glimepiride | TABLET;ORAL | 202759-001 | Jun 29, 2012 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aurobindo Pharma | NIFEDIPINE | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 213361-003 | Jul 19, 2021 | AB1 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aurobindo Pharma | RISEDRONATE SODIUM | risedronate sodium | TABLET;ORAL | 206768-001 | Oct 21, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aurobindo Pharma | TERIFLUNOMIDE | teriflunomide | TABLET;ORAL | 209638-002 | Oct 26, 2018 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Aurobindo Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Aurobindo Pharma Usa | MAXZIDE | hydrochlorothiazide; triamterene | TABLET;ORAL | 019129-001 | Oct 22, 1984 | 4,105,783 | ⤷ Start Trial |
| Aurobindo Pharma Usa | MAXZIDE-25 | hydrochlorothiazide; triamterene | TABLET;ORAL | 019129-003 | May 13, 1988 | 4,444,769 | ⤷ Start Trial |
| Aurobindo Pharma Usa | MAXZIDE | hydrochlorothiazide; triamterene | TABLET;ORAL | 019129-001 | Oct 22, 1984 | 4,444,769 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for AUROBINDO PHARMA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
